Pfizer Pipeline – Our Medicines in Development

Our pipeline of new medicines in development is the largest in the pharmaceutical industry, focusing on a broad range of unmet medical needs spanning 10 Therapeutic Areas. Pfizer invests more than $7 billion annually in the research and development of new products across more therapeutic areas than any other company in our industry. Relying on the strength of our pipeline and scientific talent, Pfizer has generated a steady stream of breakthroughs over the years. Our researchers continue to work around the clock and around the globe to ensure the best medicines for our patients in the years to come.

View an HTML or PDF version of the product candidates in Pfizer's human prescription medicine pipeline as of February 28, 2008. Content includes:

• New chemical entities in our portfolio from Phase 1 of development through to first major approval in the United States or Europe.
• New therapeutic indications or enhancements for our Phase 2 and 3 development programs and/or currently marketed medicines and selected other medicines being fast-tracked through development to reach patients quicker.

View HTML VersionDownload and Print PDF Version

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.